Ethics in Health Insurance–Only with Regulation, and/or a public option

Another article on inadequate health insurance coverage, this from the NY Times.

As noted in previous posts, the U.S. health care non-system is unique in the industrialized world. First, it’s does not provide for universal coverage. Furthermore, it allows, no it encourages, private for profit insurance companies to eliminate people who need coverage (the sick) from their roles.

I say encourages because the first responsibility of a private corporation is to make money. Having these people provide “health” insurance is an unstated sanction for them to cull their rolls of, or otherwise scam beneficiaries, particularly those who are sick and use health care. A paradox? No, it’s simply how insurers make money!

From the Times:

“Last week, a former Cigna executive warned at a Senate hearing on health insurance that lawmakers should be careful about the role they gave private insurers in any new system, saying the companies were too prone to “confuse their customers and dump the sick.””

“The number of uninsured people has increased as more have fallen victim to deceptive marketing practices and bought what essentially is fake insurance,” Wendell Potter, the former Cigna executive, testified.”

Also:

“He and the hospital say they were surprised to eventually learn that the $150,000 hospital coverage in the Aetna policy was mainly for room and board. Coverage was capped at $10,000 for “other hospital services,” which turned out to include nearly all routine hospital care – the expenses incurred in the operating room, for example, and the cost of any medication he received.”

Medicynical Note: The mythical free market in health care has never existed. And given the complexity of health care, the myriad conflicts of interest among the participants (patients, docs, institutions, patent holders, insurers), a so-called “free market”would never work to decrease costs. The proponents of such schemes inexplicably omit addressing the issues of the poor, the working poor, the sick and the asymmetry of information available (costs, options, outcomes) that would tend to distort such a “new” “free market” system.

So, if we are to reform health care coverage, we are left with what must be a highly regulated insurance scheme. Insurers would offering some standard government mandated clearly defined package of coverage using community rates (as opposed to individual ratings) with extra options at extra costs. They would compete with each other on price and service. To keep these people honest a competing public insurance program would provide an objective benchmark from which to rate the value of the private company’s offerings.

Powered by Zoundry Raven

Health Care Costs– Insurers really don’t Care

This today in the Seattle Times emphasizes the holes in todays health insurance policies. Insurers, particularly the for profit ones, are not about financing care but about assuring profits. What’s happens when you really are sick? Where can we draw the line on care?

“”It’s not just the uninsured. It’s people who have insurance that doesn’t protect them” who are fueling the hunger for reform, said Sara Collins, an economist and a vice president at The Commonwealth Fund, a private health-care foundation in New York.”

“Until about a year ago, Moody and Krull lived comfortably on her earnings as an associate broker for Windermere Real Estate. But despite their income and his seemingly gold-plated coverage, he can’t get either a second organ transplant or an expensive drug that might eradicate his hepatitis C without risking financial peril.”

:When she first enrolled in a Premera plan in 1995 after a di”vorce, she remembers that it cost only a few hundred dollars a month.:

“In 2000, she married Moody and added him to her policy. Though affordable at first, their premiums kept rising sharply. Their combined monthly premiums now total $1,746.”

Read the article to get the full flavor of their predicament. These are not the working poor or the uninsured.

Medicynical note: It is ironic that the goal of health insurers is to limit services to those who need health care most.

Forcing people onto the individual market (as opposed to providing group based rates) is the first step. Individuals have no leverage and are rated by their medical need. Premiums are routinely raised to exorbitant levels. As noted in the article people who need the most services are offered policies with unrealistically low limits and find their premiums raised to unaffordable levels (in the case cited over $1700/month).

Any new system should require community ratings. and a standardized coverage structure. both of which are anathema to the private insurance crowd or alternatively mandate a government sponsored program that will offer same.

Powered by Zoundry Raven

More Comparison Studies: Capecitabine (Xeloda) vs Standard Chemotherapy

In an attempt to prevent recurrence of breast cancer, chemotherapy is given after surgery. This is known as adjuvant chemotherapy.

One of the standard adjuvant regimens is CMF (cyclophosphamide, methotrexate, and 5-FU). Compared to other adjuvant regimens the toxicity is moderate but all the drugs are given intravenously. About 15 years ago Roche developed capecitabine (Xeloda) an oral drug that is simply 5FU in oral form. The cost of this drug is several hundred times (yes you read that correctly) that of the intravenous drug but the thought apparently was that the drug would save visits to infusion centers, which are also expensive.

Now, as reported in NEJM there is evidence that the use of capecitabine is inferior to CMF as adjuvant treatment of breast cancer in women over age 65. Unfortunately it’s taken 15 years to find this out.

Medicynical note: This experience is yet another example of why we need to compare treatment regimens. It’s counter intuitive to argue against this notion unless you are a drug company. Or an insecure physician who’s ego can’t deal with another source of information, besides the bias offered by pharmaceutical companies.

Powered by Zoundry Raven

Finally, ASCO has a concern about costs? The Need for Comparison Studies

From Forbes:

“But many companies seem to be maximizing cancer profit instead. Big drug companies are making big money off smaller and smaller improvements in cancer care. Newfangled cancer drugs can cost $50,000 a year, and that doesn’t mean they will add a year to the patient’s life–you might spend $50,000 for a year and extend the patient’s life by only weeks.”

Regarding Avastin:

“The hope was that further studies of Avastin in other types of cancer or in earlier stages of the disease would show even greater survival benefits. But they haven’t. In several breast-cancer trials–including a new one being presented at the meeting this weekend–Avastin slowed the progression of disease but did not extend patient survival at all. But doctors still use the drug in treating breast cancer because they figure it helps symptoms, even if patients don’t live longer. Avastin costs up to $55,000 a year.”

More:

“Roche is also combining other expensive drugs with Avastin. One study at the meeting showed that adding Tarceva……. delayed by one month the median time it takes lung tumors to grow. “

Medicynical note: ONE MONTH delay for $50,000. Terrific.

Where is the value? Meanwhile the drumbeat of studies showing very limited improvement but very high costs continues.

Also regarding Avastin:

“Avastin failed to prevent colon cancer from recurring after surgery. In the first year of treatment, more patients who got Avastin remained free of detectable cancer. But after a year, the drug was stopped, and by the end of the study, the apparent initial benefit had faded completely.”

In fact most people who receive drugs after surgery have no risk at all for recurrence. For those with what’s called Duke’s C disease the risk of recurrence is about 35-40%. Treatment with chemotherapy with or without Avasatin decreases the risk of recurrence by 15%. That means 20-25% recur no matter what we do. That also means that around 80% of people receiving these drugs get no benefit at all from chemo (the 60% without risk of recurrence and the 20% who recur no matter what we do).

The costs of these type treatments are astronomical. The drug company’s hopes of having $50,000/year drugs used on all patients are deal busters. I can’t think of a better poster child for comparison studies than those cited above.

Powered by Zoundry Raven

Comparison Study of Taxanes (Taxotere) in Early Breast Cancer Shows no Survival Benefit

It’s fascinating to consider the reasons why anyone opposes the concept of comparison studies to determine the benefit of a treatment. In cancer treatments are extremely expensive, and toxic. Launching patients into therapy without considering the benefit and costs is reckless.

In the May 16th Lancet a study showed no survival improvement when Taxotere was added to standard anthracycline (Epirubicin in this case) adjuvant chemotherapy (the TACT trial).

“At a median follow-up of 62 months, 75.6% of patients who received docetaxel plus anthracycline chemotherapy remained disease free, compared with 74.3% who did not receive docetaxel. The proportion of patients who reported any acute grade 3 or 4 adverse event was significantly greater among patients who received docetaxel.”

But it does add to toxicity:

“The proportion of patients reporting any acute grade 3 or 4 toxicity that occurred during treatment and up to 30 days afterward was significantly greater among those receiving docetaxel.”

The authors do point out that there may be subgroups who benefit. But given the cost and toxicity, adding a Taxane to standard chemotherapy needs further study and verification of efficacy.

Comparing treatments is part of the scientific method. Using this information to inform treatment options is rational medicine and should be encouraged.

Powered by Zoundry Raven

It’s the Money

Fascinating article in The New Yorker (June 1, 2009) on the variations in health care costs. Atul Gawande visits one of the the most expensive Health Care Markets, McAllen Texas, and looks at the reasons.

No surprises here, but nice documentation and explanation of the issues.

Powered by Zoundry Raven

A Week of Cancer News–Be Cynical!!

The American Cancer Society leads off the week with the good news that cancer deaths are continuing their slow decline. The data from 2006 attributes most of the improvement to smoking cessation and earlier diagnosis (particularly in colon cancer). We can expect to inundated with more cancer news from the ASCO (American Society of Clinical Oncology) starting this weekend–watch out for the hype and overstatements!

“The new rate shows 181 cancer deaths per 100,000 people. That was down from about 184 in 2005.”

“The CDC recently reported death rates fell for:

• Lung and trachea cancers, from 54 deaths per 100,000 in 2005 to 51.5 in 2006.

• Colorectal cancers, from 18 to 17 per 100,000.

• Breast cancer, from 27 to 23.5 per 100,000.”

It’s wonderful that fewer people are dying but it should be noted that the most effective intervention was the cheapest–prevention. By having fewer smokers in our population there were few people with lung and related cancers.

Early diagnosis also is an effective intervention. Much of the improvement in outcomes of such diseases as colon, breast and prostate cancer have nothing to do with outrageously expensive treatments but rather are due to early diagnosis and treatment because of aggressive screening for the disease–yes I know prostate screening is somewhat controversial but deaths from prostate cancer have declined since we started screening in the early 90’s.

Treatment is least effective means of extending life. Yes there are successes, such as leukemia, some lymphomas, and testicular cancer. But the survival improvement from aggressive treatment of most advanced cancers has been stagnant for 30 years. Whether new $100,000/year drugs will change this has yet to be proven–so far the data casts doubt on the cost-efficacy, and utility of such expensive treatments.

Powered by Zoundry Raven

Miami’s Health Care Costs: What Happened to Supply and Demand?

Medicine’s costs confound economists. Classical economic theory (I’m not an economist, correct me if I’m misinterpreting) would have you believe that as supply increases demand is met and prices stabilize. In health care as supply increases, demand increases and prices increase. Health care is simply not a reasoned rational system.

Consider Miami: (Time, May 20,2009)

“the 2008 average private-provider costs for a Miami family of four – $20,282 – as the highest among the 14 major U.S. cities it studied, adding that more than 40% of that amount came out of Miamians’ own pockets.”

“Miami’s inordinate health-care outlay – 20% more than the national average – “is not a pretty picture,””

“That’s especially true since Miami-Dade County also has one of the country’s lowest median incomes ($43,495).”

“”South Florida has an “excess capacity of health-care providers and institutions,” Quick notes. And to make sure they all get a piece of the action, they’ve created a wasteful and ill-coordinated system of health-care redundancies, from unnecessary MRIs to inpatient treatment that too often could have been cheaper outpatient treatment. Miami-Dade, for example, has one of the nation’s highest hospital readmission rates – and more MRI machines than Canada.” (Medicynical emphasis)

Medicynical Note: For-profit medicine is simply for profit. In Miami, efficiency and even the patient’s welfare comes second. Can we learn from Miami?

Powered by Zoundry Raven

Faith? or Ignorance

In many instances whether a person opts for treatment or not the outcome will be the same.

Hodgkin’s disease, a type of lymphoma, is different. Treatment will cure the great majority of patients. Without it the disease is almost always fatal.

The story of the child in Minnesota, Daniel Hauser, with Hodgkins disease illustrates a parent making a bad decision based on faith, and fear. Hopefully the mother who is hiding somewhere with the child will come to her senses and give the child the best chance he has for cure, which is conventional chemotherapy and/or radiation.

The management of Hodgkin’s disease is one of the great successes of oncology and denying someone access to treatment is indeed criminal. Amazing that this should be happening in a modern country.

Powered by Zoundry Raven

Conflicts of Interest:Medtronics and Infuse

Conflicts of interest continue to bedevil medical information.

I just received my Amgen sponsored American Society of Clinical Oncology education booklet and at the meetings later this month there will be all manner of company sponsored events. Many of the speakers will have noted their paid employee/consultant status for sponsoring companies.

This from the NY Times suggests that our system of research support and clinicians on the payroll of drug companies has problems.

“A former surgeon at Walter Reed Army Medical Center, who is a paid consultant for a medical company, published a study that made false claims and overstated the benefits”

“reported that a bone-growth product sold by Medtronic Inc.had much higher success in healing the shattered legs of wounded soldiersat Walter Reed than other doctors there had experienced,”

“A former Walter Reed colleague, Dr. David W. Polly Jr., who is also a Medtronic consultant, (Medicynical emphasis) said he believed that Dr. Kuklo’s data was “strong””

“The results reported by Dr. Kuklo in his Infuse study “suggested a much higher efficacy of the product being researched in the article than is supported by the experience of the purported co-authors,”

Medicynical note: What’s a medicynic to do? View company sponsored studies with suspicion? Disregard all company sponored drug studies? Look for studies not tainted by conflicts of interest? Hope that in the future comparison studies of efficacy (opposed by drug companies) clarify the benefits and risk of various treatments?

Come to think of it, why in the world would companies dedicated to knowledge and the improvement of medical outcomes oppose studies of efficacy?

Powered by Zoundry Raven